- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03021798
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over (SARA-OBS)
Characterising SARcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over at Risk of Mobility Disability. An OBServational Clinical Trial (SARA-OBS)
The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US.
300 community dwelling older adults (men or women≥65 years) reporting loss of physical function and at risk of mobility disability, will undergo mobility functional evaluation and Dual-energy X-ray Absorptiometry DXA scan for body composition determination twice, at six-month interval.
Participants aged ≥ 65 years complaining of poor physical function will be selected to perform SPPB (Short Physical Performance Battery)tests. Those with SPPB scores ≤ 8/12 will be selected to perform body composition analysis with DXA Scan. Participants with ALM/BMI < 0.789 in men and 0.512 in women will be included. The investigational phase will comprise two main visits: the inclusion visit and the 6-month visit. Both the 6-minute walk distance test and the 400-metre walking test will be administered at the main visits. Patient Reported Outcomes (PROs) will be completed by the patients at the same visits.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The SARA-OBS is a phase 2 clinical trial, with no investigational product and no therapeutic intervention. It will be conducted in three European countries, Belgium, France and Italy, and in the US.
300 community dwelling older adults (men or women≥65 years) reporting loss of physical function and at risk of mobility disability, will undergo mobility functional evaluation and Dual-energy X-ray Absorptiometry DXA scan for body composition determination twice, at six-month interval.
The general objective is to characterise sarcopenia including "sarcopenic obesity" in a population of older persons living in the community and at risk of mobility disability; evaluate their physical performance and body composition in view of the design of a phase 2 clinical study on the efficacy and safety of BIO101 on the prevention of mobility disability in the at-risk community dwelling older adults (≥65 years) reporting loss of physical function.
The primary objective characterise sarcopenia including sarcopenic obesity, in older persons at risk of mobility disability. Sarcopenia will be defined according to the criteria of the Foundation of NIH; the risk of mobility disability will be operationalised by the Short Physical Performance Battery (SPPB). For this purpose, the 6-minute walking distance and the 400-meter walking test will be evaluated at 6-month intervals, in the absence of any therapeutic intervention. The incident rate of change will be estimated on the sample and pre-specified subgroups (e.g. gender, SPPB baseline score, etc.).
Two important Secondary Objectives are also included :
- To evaluate muscle strength (handgrip/knee extension) and stair power climbing test
- To evaluate self-administered quality-of-life tests as putative patient reported outcomes (PROs): Short Form Health Survey (SF-36) and Sarcopenia Quality of Life (SarQol) for all subjects; in addition, TSD-OC for participants with BMI≥30
Exploratory objectives are :
- To measure tentative biomarkers of sarcopenia and poor physical performance, and test their correlation with physical function change over the study observation.
- To record actimetry via a connected wearable device, in order to describe daily physical activity and possibly identify patterns predictive of improvement/worsening of physical function.
Primary endpoints are the 6-minute Walk Test/400m Walking Test and Co-Primary endpoints are SF-36 and SarQoL for all subjects; additionally TSD-OC for subjects with BMI ≥ 30.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, 4020
- Université de Liège
-
-
-
-
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon Sud 165 Chemin du Grand Revoyet
-
Toulouse, France
- Gérontopole Toulouse
-
-
-
-
-
Roma, Italy, 00185
- Sapienza University of Rome
-
-
-
-
Florida
-
Gainesville, Florida, United States, 32611
- Institut On Aging
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Jean Mayer USDA Human Nutrition research Center on Aging Tufts University
-
-
New York
-
New York, New York, United States, 10027
- Columbia University New York
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women aged ≥ 65 years and living in the community, reporting loss of physical function
- Short Physical Performance Battery (SPPB) score ≤ 8
- ALM/BMI < 0.789 in men and 0.512 in women, by DXA scan
Exclusion Criteria:
- Unable or unwilling to provide informed consent
- Unable to understand and perform the functional tests, as judged by the Investigator
- Current treatment with anabolic drugs, i.e. testosterone
Clinical conditions:
- Current diagnosis major psychiatric disorders.
- Alcohol abuse or dependence
- Severe arthritis
- Cancer requiring active treatment
- Lung disease requiring regular use of supplemental oxygen
- Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents
- Severe cardiovascular disease (including New York Heart Association [NYHA] class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable defibrillator, or uncontrolled angina)
- Parkinson's disease or other progressive neurological disorder
- Renal disease requiring dialysis
- Chest pain, severe shortness of breath, or occurrence of other safety concerns during the baseline the 6MWT, or the 400-meter walk test
- Current physical/rehabilitation therapy
- Current enrolment in another clinical trial
- Concomitant condition implying life expectancy ≤ 6 months
- Any other condition precluding the regular participation to the clinical trial, as judged by the Investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-minute or 400 meters walk.
Time Frame: Change from Baseline 6 minute or 400 meters to measurement at 6 months.
|
The 6 minutes walking distance is a functional exercise capacity test that involves measuring the distance covered by a participant within a specified time of 6 minutes.
The 400 meter walking test is a measure of how long it will take for a volunteer to complete the specified 400 meters distance.
|
Change from Baseline 6 minute or 400 meters to measurement at 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SPPB
Time Frame: Change from Baseline SPPB to measurement at 6 months.
|
Physical performance tests corresponding to standing balance, walking speed and chair stand will be assessed
|
Change from Baseline SPPB to measurement at 6 months.
|
DEXA
Time Frame: Change from Baseline DEXA to measurement at 6 months.
|
Body composition especially Lean Body Mass and Fat Mass will be measured.
This will allow definition of the appendicular Lean Body mass.
|
Change from Baseline DEXA to measurement at 6 months.
|
Stair Climb Power Test
Time Frame: Change from Baseline Stair Climb Power Test to measurement at 6 months.
|
The ability to ascend and descend stairs (9 stairs of 20 cm height) will be assessed in a specific period of time
|
Change from Baseline Stair Climb Power Test to measurement at 6 months.
|
Actimetry
Time Frame: Change from actimetry at Month1 to measurement at 6 months.
|
The continuous physical activity of the volunteers will be recorded using a specific device during the 6-month study period.
|
Change from actimetry at Month1 to measurement at 6 months.
|
Grip strength
Time Frame: Change from Baseline Grip Strength to measurement at 6 months.
|
The grip strength will be measured using the appropriate dynamometer.
Strength will be measured 3 times for both hands and the highest value will be kept for further analysis.
|
Change from Baseline Grip Strength to measurement at 6 months.
|
Knee extension
Time Frame: Change from Baseline knee extension to measurement at 6 months.
|
The knee extension measurement will be performed using isokinetic dynamometer.
|
Change from Baseline knee extension to measurement at 6 months.
|
Patient Reported Outcome : SF-36
Time Frame: Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Electronically self administrated Patient Reported Outcome SF-36 will be assessed a SF-36 questionnaire.
|
Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Patient Reported Outcomes : SarQoL
Time Frame: Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Electronically self administrated Patient Reported Outcome SarQoL will be assessed through the SarQoL questionnaire.
|
Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Patient Reported Outcomes TSC-OD for patients with BMI>30
Time Frame: Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Electronically self administrated Patient Reported Outcomes will be assessed through the TSD-OC questionnaire for volunteers having BMI>30
|
Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Patient Reported Outcomes (PAT-D)
Time Frame: Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Electronically administrated Patient Reported Outcome will be assessed with assistance of the investigator through the PAT-D questionnaire.
|
Change from Baseline Patient Reported Outcome to measurement at 6 months.
|
Biomarkers
Time Frame: Change from Baseline Biomarkers to measurement at 6 months
|
Biomarkers specific to Sarcopenia and to the Renin Angiotensin System ( Aldosterone; Renin; Myostatin; PIIINP; IL-6; hsCRP etc....) will be measured at baseline and at 6 months.
|
Change from Baseline Biomarkers to measurement at 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Samuel Agus, MD, Biophytis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIO101-CL02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Weakness
-
St. Luke's-Roosevelt Hospital CenterCompletedFall Risk | Quadriceps Muscle Weakness | Adductor Muscle WeaknessUnited States
-
Association Pro-arteActive, not recruitingWeakness, Muscle | AmyotrophiaFrance
-
University of Central ArkansasCompletedPelvic Floor Muscle WeaknessUnited States
-
Ludwig Boltzmann Institute of Electrical Stimulation...Medical University of Vienna; European Union; Comenius University; Ministry of...CompletedMuscle Weakness Condition | Therapy EffectAustria, Slovakia
-
Rutgers, The State University of New JerseyRecruitingPhysical Disability | Muscle Atrophy or Weakness | Muscle Loss | Physical Inactivity | Delirium in Old Age | Hospital Acquired Condition | Weakness, MuscleUnited States
-
University of MilanCompleted
-
University of Central FloridaCompletedMuscle Weakness | Muscle Atrophy | Muscle Loss | Weakness, Muscle | Injury, KneeUnited States
-
University of Texas Southwestern Medical CenterTerminatedMuscle Cramp | Statin Adverse Reaction | Weakness, Muscle | AcheUnited States
-
Riphah International UniversityCompletedMuscle Weakness ConditionPakistan
-
Damanhour UniversityCompletedNeuromuscular Electrical Stimulation | ICU Acquired Muscle WeaknessEgypt
Clinical Trials on No Drug and no aspecific intervention
-
The Hong Kong Polytechnic UniversityRecruitingChronic Low Back PainHong Kong
-
Ehsan M saiedUnknownConvulsive Seizures
-
Taichung Veterans General HospitalHungkuang UniversityCompletedVertebral Compression Fracture | Posture
-
Oneness Biotech Co., Ltd.Completed
-
Fraunhofer-Institute of Toxicology and Experimental...UCB PharmaCompleted
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
Yale UniversityUniversity of Washington; University of New Mexico; Desert Institute for Spine... and other collaboratorsTerminatedLumbar Disc HerniationUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
BayerCompletedAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan